Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

Just nine months after announcing a hefty plan to cut costs, Bristol Myers Squibb has gone one better, revealing a new goal to save even more money. The new plan, which has been dubbed a ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations. The quarter's results, reaffirmed Bristol Myers Squibb's financial health and ...

The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Pharma giant Bristol Myers Squibb is planning another round of cost cutting as part of a broader restructuring plan. Under the “strategic productivity initiative” announced Feb. 6, the ...

However, on February 3, Jefferies maintained a Buy rating on Bristol-Myers Squibb (NYSE: BMY). BMY market cap is currently $116.5B and has a P/E ratio of -12.97. Read More on BMY: Bristol-Myers ...